

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: William J. McBRIDE et al.
Title: RADIOMETAL-BINDING PEPTIDE
ANALOGUES
Appl. No.: 08/893,749
Filing Date: 10/02/2000
Examiner: Unassigned
Art Unit: Unassigned



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56.

The submission of any documents herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

CONCISE EXPLANATION OF
RELEVANCE OF EACH DOCUMENT



Applicants are submitting herewith on Form PTO-1449, a listing of the documents cited by or submitted to the Patent Office in parent application Serial No. 08/893,749, filed July 11, 1997. The relevance of these documents is explained in the parent application.

As provided in 37 C.F.R. §1.98(d), copies of the documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. 08/893,749 filed July 11, 1997.

Since this Information Disclosure Statement is being filed in compliance with 37 C.F.R. §1.97(b) within three (3) months of the filing date, no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date October 2, 2000

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5427
Facsimile: (202) 672-5399

By Bernhard D. Saxe #33,665

Bernhard D. Saxe
Attorney for Applicant
Registration No. 28,665

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

018733/0997

SERIAL NO.

08/893,749

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

William J. McBRIDE et al.

FILING DATE

10/02/2000

GROUP ART UNIT

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	4,822,890	4/89	Bolin	548	344	
	A2	5,225,180	7/93	Dean et al.	424	1.1	
	A3	4,564,472	1/86	Ueda et al.	260	113	
	A4	5,227,474	7/93	Johnson et al.	534	558	
	A5	5,449,761	9/95	Belinka, Jr, et al.	534	10	
	A6	5,753,206	05/98	McBride et al.	424	1.69	
	A7	5,080,884	01/92	McBride et al.	424	1.1	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A8	96/40756	12/96	WIPO				
	A9	91/01144	2/91	WIPO				
	A10	93/21962	11/93	WIPO				
	A11	93/25244	12/93	WIPO				
	A12	94/23758	10/94	WIPO				
	A13	94/26294	11/94	WIPO				
	A14	94/28942	12/94	WIPO				
	A15	0 536 741	4/93	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A16	Virgolini et al., "Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors" <u>The New England Journal of Medicine</u> pp. 1116-1121 (1994)
	A17	Virgolini et al., "Vasoactive Intestinal Peptide Receptor Scintigraphy" <u>The Journal of Nuclear Medicine</u> 36:1732-1739 (1995)
	A18	Lister-Jamcs et al., "Radiopharmaceutical Chemistry: Protein, Peptides, Antibodies I" <u>No. 370</u> 36:91P, (1995)
	A19	Pearson et al., "Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies" <u>J. Med. Chem.</u> 39:1361-1371 (1996)
	A20	Krenning et al., "Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide" <u>The Journal of Nuclear Medicine</u> 33:652-658 (1992)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

018733/099

SERIAL NO.

08/893,749

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

William J. McBRIDE et al.

FILING DATE

10/02/2000

GROUP ART UNIT

Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A21

Wright et al., "The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of melanoma" The British Journal of Radiology 65:112-118 (1992)

A22

Reubi, "In Vitro Identification of Vasoactive Intestinal Peptide Receptors in Human Tumors: Implications for Tumor Imaging" The Journal of Nuclear Medicine 36:1846-1853 (1995)

A23

Maina et al., "Synthesis, Radiochemical and Biological Evaluation of ^{99m}Tc[N4(D)Phe¹]-Octreotide, a New Octreotide Derivative with High Affinity for Somatostatin Receptor" The Journal of Nuclear Biology and Medicine pp.452 (1994)

A24

Bajusz et al., "Highly potent metalloproteinase analogues of luteinizing hormone-releasing hormone" Proc. Natl. Acad. Sci. USA 86:6313-6317 (1989)

A25

Felix et al., "Synthesis, biological activity and conformational analysis of cyclic GRF analogs" J. Peptide Protein Res. 32:441-454 (1988)

A26

Edwards et al., "Generally Applicable, Convenient Solid-Phase Synthesis and Receptor Affinities of Octreotide Analogs" J. Med. Chem. 37:3749-3757 (1994)

A27

Bienstock et al., "Conformational Analysis of a Highly Potent Dicyclic Gonadotropin-Releasing Hormone Antagonist by Nuclear Magnetic Resonance and Molecular Dynamics" American Chemical Society pp.3265-3273 (1993)

A28

Barbacci et al., "The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding" The Journal of Biological Chemistry 270:9585-9589 (1995)

A29

Haskell-Luevano et al., "Characterizations of the Unusual Dissociation Properties of Melanotropin Peptides from the Melanocortin Receptor, hMC1R" J. Med. Chem. 39:432-435 (1996)

A30

Al-Obeidi et al., "Design of a New Class of Superpotent Cyclic α -Melanotropins Based on Quenched Dynamic Simulations" J. AM. Chem. Soc. 111:3413-3416 (1989)

A31

O'Donnell et al., "Ro 25-1553: A Novel, Long-Acting Vasoactive Intestinal Peptide Agonist. Part I: In Vitro and In Vivo Bronchodilator Studies" The Journal of Pharmacology and Experimental Therapeutics 270:1282-1294 (1994)

A32

Virgolini et al., "Cross-Competition between Vasoactive Intestinal Peptide and Somatostatin for Binding to Tumor Cell Membrane Receptors¹" Cancer Research pp.690-700 (1994)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

09/676783
10/02/00
U.S. PTO
Jc882